ACADIA Pharmaceuticals Inc (MEX:ACAD)
MXN 362 (0%) Market Cap: 75.95 Bil Enterprise Value: 61.93 Bil PE Ratio: 11.51 PB Ratio: 3.47 GF Score: 73/100

Q1 2026 ACADIA Pharmaceuticals Inc Earnings Call Transcript

May 06, 2026 / 08:30PM GMT
Release Date Price: MXN381
Operator

Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals first-quarter 2026 earnings conference call. (Operator Instructions)

Thank you. I would now like to turn the conference over to Albert Kildani, Senior Vice President, Investor Relations and Corporate Development. Please go ahead.

Albert Kildani
ACADIA Pharmaceuticals Inc - Senior Vice President, Investor Relations and Corporate Communications

Good afternoon, and thank you for joining us on today's call to discuss ACADIA's first-quarter 2026 financial results.

Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today are Elizabeth Thompson, Ph.D., Executive Vice President, Head of Research and Development, who will provide an update on our pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot